False-positive screening results in the Finnish prostate cancer screening trial

British Journal of Cancer

Volumn 102, Issue 3, 2010, Pages 469-474

  Kilpelainen T P ^a   Tammela, T L J ^a   Maattanen L ^b   Kujala, P ^c   Stenman, U H ^d   Ala Opas, M ^d   Murtola, T J ^a,e   Auvinen, A ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Central Finland Central Hospital   (Finland)

Author keywords

Mass screening; Prostatic neoplasms; PSA; Randomised controlled trials; Sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; FALSE POSITIVE RESULT; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; BIOPSY; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FINLAND; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 76349099582     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605512     Document Type: Article

References (22)

1. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319
2. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL (1994) Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 151: 1283-1290
3. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE (2009) Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 7: 212-222
4. Djavan B, Remzi M, Marberger M (2003) When to biopsy and when to stop biopsying. Urol Clin North Am 30: 253-262
5. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM (2005) Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174: 877-881
6. Ford ME, Havstad SL, Demers R, Johnson CC (2005) Effects of false-positive prostate cancer screening results on subsequent prostate cancer screening behavior. Cancer Epidemiol Biomarkers Prev 14: 190-194
7. Fowler Jr FJ, Barry MJ, Walker-Corkery B, Caubet JF, Bates DW, Lee JM, Hauser A, McNaughton-Collins M (2006) The Impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral and medical care outcomes. J Gen Intern Med 21: 715-721
8. Koskimäki J, Hakama M, Huhtala H, Tammela TL (1998) Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. Br J Urol 81: 364-369
9. Lafata J, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson C (2004) The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev 13: 2126-2132
10. Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA (1999) Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 150: 848-860
11. Määttänen L, Hakama M, Tammela TLJ, Ruutu M, Ala-Opas M, Juusela H, Martikainen P, Stenman UH, Auvinen A (2007) Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer 96: 56-60
12. Mäkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TLJ (2002) Acceptability and compliations of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology 60: 846-850
13. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global Cancer statistics, 2002. CA Cancer J Clin 55: 74-108
14. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM (1999) Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol 161: 1174-1179
15. Rowe EW, Laniado ME, Walker MM, Patel A (2005) Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study. BJU Int 95: 1249-1252
16. Schröder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R (1998) Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 90: 1817-1823
17. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators (2009) Screening and prostate cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328
18. Stenman UH, Finne P, Zhang W, Leinonen J (2000) Prostate-specific antigen and other prostate cancer markers. Urology 56: 893-898
19. Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 33: 365-369
20. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman Jr CA (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level <or; 4ng per millimeter. N Engl J Med 350: 2239-2246
21. Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101: 1325-1329
22. Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan DW, Carter HB (2002) Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 167: 2484-2487. (Pubitemid 34533151)